Histological improvement at 4 weeks (dichotomous) · active EoE pediatric patients
It is very uncertain whether swallowed fluticasone changes histological improvement at 4 weeks (dichotomous) compared with oral prednisone (very low certainty).
1 finding from 1 review
Histological improvement (continuous) · active EoE pediatric patients
1 finding from 1 review
Histological improvement (continuous) · active EoE patients
1 finding from 1 review
Endoscopic improvement (dichotomous) · active EoE pediatric patients
It is very uncertain whether swallowed fluticasone changes endoscopic improvement at 4 weeks (dichotomous) compared with oral prednisone (very low certainty).
1 finding from 1 review
Endoscopic improvement (continuous) · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · active EoE pediatric patients
It is very uncertain whether swallowed fluticasone changes withdrawals due to adverse events at 4 weeks compared with oral prednisone (very low certainty).
1 finding from 1 review
Clinical improvement (dichotomous) · active EoE patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical improvement (continuous) · active EoE patients
1 finding from 1 review
Histological improvement (dichotomous) · active EoE patients
Oral viscous budesonide showed no clear difference in histological improvement at study endpoint (dichotomous) compared with swallowed fluticasone (low certainty).
1 finding from 1 review
Histological improvement (continuous) · active EoE patients
1 finding from 1 review
Endoscopic improvement (dichotomous) · active EoE patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Endoscopic improvement (continuous) · active EoE patients
1 finding from 1 review
Withdrawals due to adverse events · active EoE patients
Oral viscous budesonide showed no clear difference in withdrawals due to adverse events at 8 weeks compared with swallowed fluticasone (low certainty).
1 finding from 1 review
Endoscopic improvement (dichotomous) · active EoE patients
Corticosteroids showed no clear difference in endoscopic improvement (dichotomous) compared with placebo (low certainty).
1 finding from 1 review
Clinical improvement (dichotomous) · active EoE patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical improvement (continuous) · active EoE patients
1 finding from 1 review
Histological improvement (dichotomous) · active EoE patients
It is very uncertain whether esomeprazole changes histological improvement at 8 weeks (dichotomous) compared with fluticasone (very low certainty).
1 finding from 1 review
Histological improvement (continuous) · active EoE patients
1 finding from 1 review
Endoscopic improvement (dichotomous) · active EoE patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Endoscopic improvement (continuous) · active EoE patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found